Explanatory notes
Explanatory notes to the business of the AGM
Ordinary business
Resolution 1 – Report and accounts
The Directors are obliged to lay the annual financial statements, the reports of the Directors’ and the Independent Auditor’s Report before shareholders each financial year at a general meeting. These reports are contained in the Company’s Annual Report and Accounts 2022, which is available on the Company’s website corporate.abcam.com.
Resolution 2 – Annual Report on Remuneration
In accordance with section 439 of the Companies Act 2006 (Act), this resolution seeks shareholder approval of the Annual Report on Remuneration as contained on pages 49 to 59 of the Annual Report and Accounts 2022. It sets out the pay and benefits received by each of the Directors for the period ended 31 December 2022. In line with legislation this vote will be advisory and in respect of the overall remuneration package.
Resolutions 3 and 4 – Appointment of auditor and auditor’s remuneration
The Company is required to appoint an auditor at each general meeting at which accounts are laid before the shareholders to hold office until the next such meeting.
Resolution 4 proposes the re-appointment of PricewaterhouseCoopers LLP (PwC) as auditor of the Company. PwC has indicated that it is willing to continue to act as the Company’s auditor for a further year. The Audit and Risk Committee has reviewed PwC’s effectiveness and the effectiveness of its audit process and recommends its re-appointment.
Resolution 5 seeks shareholder consent for the Audit and Risk Committee to set the remuneration of the auditor.
Resolutions 5 to 13 – Election and re-election of Directors
The Directors believe that effective corporate governance, appropriate to the Group’s size and stage of development, will assist in the delivery of corporate strategy, the generation of shareholder value and the safeguarding of shareholders’ long-term interests. Accordingly, all members of the Board will stand for re-election or, in the case of Luba Greenwood, election at the AGM.
Biographical details of the Directors standing for election or re-election are set out below, including the reasons why their contributions are, and continue to be important to the Company’s long term sustainable success. The Board believes this information is sufficient to enable shareholders to make an informed decision on their elections.
Peter Allen, BA ACA
Chairman
Appointed
June 2018
Committee membership
Nominations Committee (Chair)
Remuneration Committee
Background
Peter has nearly 30 years’ experience as an executive director, non-executive director and chairman in a wide range of life science companies playing a significant role in their growth. From 2012 to 2021, Mr Allen served as the Chairman of Clinigen plc. From 2011 to 2022, Mr Allen served as a non executive director and then the Chairman of Oxford Nanopore Technologies plc. From 2015 to 2020, Mr. Allen served as the Chairman of Diurnal Group plc. From 2009 to 2012, Mr. Allen served as Chairman of Proximagen Neurosciences plc, from 2005 to 2013 he served as Chairman of ProStrakan Group plc, including as interim CEO from 2010 to 2011, and he served as CFO and Deputy CEO of Celltech Group plc from 1992 to 2004.
Current external appointments
Peter is currently Non Executive Chairman of Advanced Medical Solutions plc. He is a Non Executive Director of Istesso Ltd.
Skills, experience and contribution
A chartered accountant by background, Peter brings to Abcam his experience as a chairman and board member and has substantial experience in M&A, international growth, fundraising and investor relations, as well as the commercialisation of intellectual property.
Abcam plc Notice of Annual General Meeting 2023
6